Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Tobevibart + Elebsiran in Hepatitis Delta Virus. The expected timing is based on the latest available company guidance and may change.
SOLSTICE & ECLIPSE trials. 6/5/24- Reported prelim 12-wk & 24-wk data. 3/13/25- Initiated trial. Presented 24-wk subgroup analysis at EASL'25. 8/4/25- Initiated ECLIPSE 2 trial. 11/3/25- Enrollment completed in ECLIPSE 1. Last patient primary completion in Q1 2026 & topline data in Q1 2027. 11/9/25- SOLSTICE wk 48 endpoint data presented at AASLD'25. 11/05/25:- ECLIPSE 1 enrollment finished about two months early with primary completion now expected in Q4 2026. Topline data for ECLIPSE 1–3 are anticipated in Q1 2027 and SOLSTICE Week 48 results are planned for oral presentation at AASLD 2025 on November 9, 2025. 01/12/26:- SOLSTICE Ph2 72/96-week data positive. ECLIPSE1 topline Q4 2026; ECLIPSE2/3 topline Q1 2027. 02/23/26:- Norgine licensed CHD combo ex-US; SOLSTICE Ph2 Week 96 showed 88% HDV RNA TND. 05/06/26:- SOLSTICE Ph2 Week 96 data to be presented at EASL Congress May 27-30, 2026; ECLIPSE timelines reiterated. 05/18/26:- SOLSTICE Week 96 oral and Week 48 subgroup data present May 29, 2026 at EASL. 08/05/26:- SOLSTICE Week 96 positive; ECLIPSE 2 enrolled; ECLIPSE 1 topline Q4 2026; ECLIPSE 2/3 Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.